-
December 10, 2012
On a good day for the market, the Nasdaq is trading up 0.6%, the S&P 500 is up 0.2% and the Dow has increased 0.3%. ...
-
December 06, 2012
The pharmaceutical industry is slowly showing signs of recovery from one of the biggest patent cliffs in recent ...
-
December 06, 2012
The pharmaceutical industry is slowly showing signs of recovery from one of the biggest patent cliffs in recent ...
-
November 15, 2012
Celgene Corporation (CELG) recently announced encouraging results on its candidate apremilast from a phase III study ...
-
November 12, 2012
Currently, the Nasdaq has declined 0.1%, the S&P 500 is unchanged and the Dow has slipped 0.1%. The recent surge in ...
-
November 12, 2012
The Nasdaq has decreased 0.1%, the S&P 500 has moved little and the Dow is trading down 0.1% so far today. The ...
-
November 08, 2012
InterMune Inc.'s (ITMN) third-quarter loss per share of 70 cents was narrower than the Zacks Consensus loss Estimate ...
-
October 25, 2012
Celgene Corporation's (CELG) third quarter 2012 earnings (excluding special items but including stock-based ...
-
October 25, 2012
Celgene (Nasdaq:CELG) announced its results for the third quarter on October 25, 2012. Celgene is a ...
-
October 23, 2012
Celgene Corporation (CELG) announced that it has received approval from the US Food and Drug Administration (FDA) ...
-
October 22, 2012
Onyx Pharmaceuticals, Inc. (ONXX) recently announced that it has finished enrolling patients for the phase III FOCUS ...
-
October 22, 2012
Celgene (Nasdaq:CELG) is expected to report increased earnings when it releases its third quarter results on ...
-
October 19, 2012
The market is having a bad day so far: the Nasdaq has slipped 1.6%; the S&P 500 is trading down 1%; and the Dow is ...
-
October 10, 2012
The Nasdaq has been relatively flat, the S&P 500 is down 0.2% and the Dow has decreased 0.5% so far today. The ...
-
October 03, 2012
Celgene Corporation (CELG) recently announced that its oncology drug, Abraxane, has performed well in a phase III ...
-
October 02, 2012
So far today, the Nasdaq has climbed 0.4%, the S&P 500 is up 0.1% and the Dow is trading down 0.2%. The healthcare ...
-
September 20, 2012
Celgene Corporation (CELG) recently announced that Oncologic Drugs Advisory Committee (ODAC) of the US Food and Drug ...
-
September 10, 2012
The Nasdaq has slipped 0.6%, the S&P 500 is unchanged and the Dow is trading up 0.1% after the morning's trading. ...
-
September 07, 2012
We are maintaining our Neutral recommendation on Celgene Corporation (CELG) with a target price of $76.00. The stock ...
-
September 07, 2012
Recently, Celgene Corporation (CELG) announced encouraging data from two phase III studies (PALACE-2, PALACE-3), ...
